NCT00640627 - Efficacy and Safety of Celecoxib Versus Placebo in the Treatment of Patients With Osteoarthritis of the Knee Who Were Unresponsive to Naproxen and Ibuprofen | Biotech Hunter

Enrollment

380

Participants

Timeline

Start Date

December 31, 2003

Study Completion Date

September 30, 2004

Conditions

Osteoarthritis, Knee

Interventions

DRUG

Celecoxib

200 mg oral capsule once daily for 6 weeks

DRUG

Placebo

Matched oral placebo for 6 weeks

Trial Locations (30)

15009

Pfizer Investigational Site, Beaver

17011

Pfizer Investigational Site, Camp Hill

19046

Pfizer Investigational Site, Jenkintown

21239

Pfizer Investigational Site, Baltimore

27401

Pfizer Investigational Site, Greensboro

30189

Pfizer Investigational Site, Woodstock

32720

Pfizer Investigational Site, DeLand

33024

Pfizer Investigational Site, Pembroke Pines

33710

Pfizer Investigational Site, St. Petersburg

34102

Pfizer Investigational Site, Naples

37130

Pfizer Investigational Site, Murfreesboro

37203

Pfizer Investigational Site, Nashville

37601

Pfizer Investigational Site, Johnson City

39232

Pfizer Investigational Site, Flowood

45040

Pfizer Investigational Site, Mason

63017

Pfizer Investigational Site, Chesterfield

66215

Pfizer Investigational Site, Overland Park

70119

Pfizer Investigational Site, New Orleans

78217

Pfizer Investigational Site, San Antonio

78705

Pfizer Investigational Site, Austin

80033

Pfizer Investigational Site, Wheat Ridge

80904

Pfizer Investigational Site, Colorado Springs

85051

Pfizer Investigational Site, Phoenix

85712

Pfizer Investigational Site, Tucson

87109

Pfizer Investigational Site, Albuquerque

89502

Pfizer Investigational Site, Reno

90723

Pfizer Investigational Site, Paramount

90806

Pfizer Investigational Site, Long Beach

92780

Pfizer Investigational Site, Tustin

98133

Pfizer Investigational Site, Seattle

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY